Current indications for anti-VEGF intravitreal therapy (IVT) include choroidal neovascularizations (CNV) due to age related macular degeneration (AMD), pathologic myopia and CNV of other origin, macular edema secondary to diabetes and retinal vein occlusion. This evidence concerns the gene VEGFA and age-related macular degeneration.